MRI-monitored transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: Preclinical studies in a rodent model

Investigative Radiology

Volumn 48, Issue 6, 2013, Pages 492-499

  Sheu, Alexander Y ^a   Zhang, Zhuoli ^a   Omary, Reed A ^a,b   Larson, Andrew C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

hepatocellular carcinoma; magnetic resonance imaging; natural killer lymphocyte; superparamagnetic iron oxide nanoparticles; transcatheter intra arterial delivery

Indexed keywords

POLYURETHAN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHETER; CELL LABELING; CELL VIABILITY; CONTROLLED STUDY; HISTOPATHOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROPER HEPATIC ARTERY; RAT; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; VASCULAR EQUIPMENT;

EID: 84877581134     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31827994e5     Document Type: Article

References (29)

1. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928.
2. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
3. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
4. Cabrera R, Nelson D. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;31:461-476.
5. Taketomi A, Shimada M, Shirabe K, et al. Natural killer cell activity in patients with hepatocellular carcinoma. Cancer. 1998;83:58-63.
6. Son K, Kew M, Rabson AR. Depressed natural killer cell activity in patients with hepatocellular carcinoma: in vitro effects of interferon and levamisole. Cancer. 1982;50:2820-2825.
7. Morris M, Ley K. Trafficking of natural killer cells. Curr Mol Med. 2004; 4:431-438.
8. Rabinowich H, Vitolo D, Altarac S, et al. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. J Immunol. 1992;149:340-349.
9. Sasaki A, Melder RJ, Whiteside TL, et al. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst. 1991;83:433-437.
10. Matera L, Galetto A, Bello M, et al. In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma. J Transl Med. 2006;4:49.
11. Daldrup-Link HE, Rudelius M, Piontek G, et al. Migration of iron oxideYlabeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology. 2005;234:197-205.
12. Fleige G, Seeberger F, Laux D, et al. In vitro characterization of two different ultrasmall iron oxide particles for magnetic resonance cell tracking. Invest Radiol. 2002;37:482-488.
13. Dassler K, Roohi F, Lohrke J, et al. Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105specific iron oxide nanoparticles. Invest Radiol. 2012;47:383-391.
14. Daldrup-Link HE, Meier R, Rudelius M, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005; 15:4-13.
15. Sigovan M, Kaye E, Lancelot E, et al. Anti-inflammatory drug evaluation in ApoE-/mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Invest Radiol. 2012;47:546-552.
16. Virmani S, Wang D, Harris K, et al. Comparison of transcatheter intraarterial perfusion MR imaging and fluorescent microsphere perfusion measurements during transcatheter arterial embolization of rabbit liver tumors. J Vasc Interv Radiol. 2007;18:1280-1286.
17. Tam YK, Maki G, Miyagawa B, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther. 1999;10:1359-1373.
18. Guo Y, Klein R, Omary RA, et al. Highly malignant intra-hepatic metastatic hepatocellular carcinoma in rats. Am J Transl Res. 2010;3:114-120.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
20. Bulte JW, Ben-Hur T, Miller BR, et al. MR microscopy of magnetically labeled neurospheres transplanted into the Lewis EAE rat brain. Magn Reson Med. 2003;50:201-205.
21. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969-977.
22. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246.
23. Car?llo MC, Alvarez Mde L, Quiroga AD. Interferon alfa-2b triggers transforming growth factor-beta-induced apoptosis on preneoplasticliver. Ann Hepatol. 2006;5:244-250.
24. Malvindi MA, Di Corato R, Curcio A, et al. Multiple functionalization of fluorescent nanoparticles for specific biolabeling and drug delivery of dopamine. Nanoscale. 2011;3:5110-5119.
25. Jha P, Golovko D, Bains S, et al. Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities. Cancer Res. 2010;70:6109-6113.
26. Freitas N, Salisse J, Cunha C, et al. Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. Hepatology. 2012;56:76-85.
27. Jin N, Deng J, Chadashvili T, et al. Carbogen gas-challenge BOLD MR imaging in a rat model of diethylnitrosamine-induced liver fibrosis. Radiology. 2010;254:129-137.
28. Jiang T, Kambadakone A, Kulkarni NM, et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol. 2012;47:11-17.
29. An C, Choi GH, Lee HS, et al. Assessment of preoperative magnetic resonance imaging staging in patients with hepatocellular carcinoma undergoing resection compared with the seventh american joint committee on cancer system. Invest Radiol. 2012;47:634-641